Crispr Therapeutics
Presence
Crispr Therapeutics is a company listed under the stock ticker CRSP (CH).
Executives
View the org chart displaying its 18 main executives
Most searched biographies at Crispr Therapeutics
- Samarth Kulkarni, Chief Executive Officer and Chairman of the Board
- Edd Fleming, Director
- Simeon George, Director
Popular executive movements at Crispr Therapeutics
- Christian Rommel has joined the company as Director (posted on March 14 2024).
- Phuong Morrow, Chief Medical Officer, will leave the company on Jan. 26, 2024 (posted on December 22 2023).
- Sandy Mahatme will join the company as Director in Jun. 2024 (posted on October 17 2023).
Click here to view some more movements at Crispr Therapeutics
Create your alert
to follow the executive moves at Crispr Therapeutics.
Biotechnology
Crispr Therapeutics has 2,281 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Adaptive Phage Therapeutics (United States (USA)).
Popular M&A news in Biotechnology
- Endeavor BioMedicines has just announced a $132 Million fundraising (posted on April 25 2024).
- Metsera has just announced a $290 Million fundraising (posted on April 23 2024).
- Histogen has filed for bankruptcy protection (posted on April 19 2024).
Popular contacts in Biotechnology
News
Press releases by Crispr Therapeutics
- Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With exagamglogene autotemcel (exa-cel) at the 2022 European Hematology Association (EHA) Congress | CRISPR Therapeutics
- CRISPR Therapeutics Presents Positive Results from its Phase 1 COBALT™-LYM Trial of CTX130™ in Relapsed or Refractory T Cell Malignancies at the 2022 European Hematology Association (EHA) Congress | CRISPR Therapeutics
- CRISPR Therapeutics to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference | CRISPR Therapeutics
- Vertex and CRISPR Therapeutics Announce Acceptance of Late-Breaking Abstract for CTX001™ at the 2022 Annual European Hematology Association (EHA) Congress | CRISPR Therapeutics
- CRISPR Therapeutics to Host Innovation Day on June 21, 2022 | CRISPR Therapeutics
- CRISPR Therapeutics Reports Positive Top-Line Results from Its Phase 1 CARBON Trial of CTX110™ in Relapsed or Refractory CD19+ B-cell Malignancies | CRISPR Therapeutics
- CRISPR Therapeutics Congratulates Co-Founder Emmanuelle Charpentier on Receiving the 2020 Nobel Prize in Chemistry | CRISPR Therapeutics
- CRISPR Therapeutics to Participate in Upcoming Investor Conferences | CRISPR Therapeutics
- CRISPR Therapeutics and Vertex Pharmaceuticals Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency (EMA) to CTX001™ for the Treatment of Sickle Cell Disease | CRISPR Therapeutics
- CRISPR Therapeutics to Present at the Wells Fargo 2020 Virtual Healthcare Conference | CRISPR Therapeutics
- View more press releases Close
Social media about Crispr Therapeutics
- Crispr Therapeutics on Wikipedia, Google News & Yahoo Finance
- Crispr Therapeutics on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Samarth Kulkarni 
Call Crispr Therapeutics at +41 41...
